Clinical Trial Update: A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy [Phase 2]

View source ↗

Summary

Phase 2 study assessing multiple doses of nusinersen (ISIS 396443) delivered to presymptomatic infants with genetically diagnosed spinal muscular atrophy comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Spinraza (nusinersen)

Snippet

Sponsor: Biogen | Conditions: Spinal Muscular Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2025-10-20